Contrasting Therapeutic Solutions International (OTCMKTS:TSOI) & Cybin (OTCMKTS:CYBN)

Cybin (OTCMKTS:CYBN) and Therapeutic Solutions International (OTCMKTS:TSOI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Cybin and Therapeutic Solutions International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
Therapeutic Solutions International	N/A	N/A	N/A

Insider and Institutional Ownership

17.9% of Cybin shares are owned by institutional investors. Comparatively, 5.6% of Therapeutic Solutions International shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Cybin and Therapeutic Solutions International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	1	0	3.00
Therapeutic Solutions International	0	0	0	0	0.00

Earnings & Valuation

This table compares Cybin and Therapeutic Solutions International”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	$680,000.00	302.23	-$35.93 million	($6.66)	-1.54
Therapeutic Solutions International	N/A	N/A	N/A	($0.01)	-0.04

Therapeutic Solutions International has lower revenue, but higher earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Therapeutic Solutions International, indicating that it is currently the more affordable of the two stocks.

Summary

Cybin beats Therapeutic Solutions International on 5 of the 9 factors compared between the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

About Therapeutic Solutions International

Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. It also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. In addition, the company develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology; and portfolio of immunotherapies that provides dendritic cell vaccines for cancers to Parkinson’s disease developed on StemVacs platform. Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.